Products Pipeline

/Products Pipeline
Products Pipeline 2017-12-16T01:23:47+00:00

Irofulven-1 Program

  • Irofulven – 1 drug was developed by MGI & EISAI. 
  • Objective response in 12-15% prostate and ovarian cancer patients but program shelved.
  • 30+ clinical trials and 900 patients treated.
  • Successful out-licensing to OV in 18 months.  

Irofulven-2 Program

  • Irofulven – 2 drug is a 2nd generation drug developed by MGI & UCSD.
  • A better drug in terms of Efficacy, Safety, and PK.

Tavocept Rescue Program

  • An Overall Survival (OS) of 25 months, with a 2-year survival of 51.4%, in females with advanced adenocarcinoma of the lung receiving paclitaxel/cisplatin & LP300®
  • More than 540 Patients treated.  Asian study arm responded better than non-Asian arm
  • Results in non-smoking women were also statistically significant in favor of LP300 for OS  (p=0.017) & the 2-year survival was 72% for LP300 vs. 32% for Placebo.

Partner with Us

We are a multi-national company committed to precise and efficient drug development through technology.

Contact Us